Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearing loss

Journal of Pediatric Hematology/Oncology

Volumn 26, Issue 10, 2004, Pages 649-655

  Bertolini, Patrizia ^a   Lassalle, Mathilde ^b   Mercier, Guilaine ^c   Raquin, Marie Anne ^b   Izzi, Giancarlo ^a   Corradini, Nadege ^b   Hartmann, Olivier ^b  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Groupe Recherche Audiologie Medicale   (France)

Author keywords

Carboplatin; Children solid tumors; Cisplatin; Hearing loss; Otoxicity

Indexed keywords

CARBOPLATIN; CISPLATIN; PLATINUM DERIVATIVE;

ADOLESCENT; ARTICLE; BEHAVIOR; CHILD; CONTROLLED STUDY; DISEASE COURSE; DRUG SURVEILLANCE PROGRAM; FEMALE; GERM CELL TUMOR; HEARING LOSS; HEPATOBLASTOMA; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; OSTEOSARCOMA; OTOTOXICITY; PRIORITY JOURNAL; PURE TONE AUDIOMETRY;

ADOLESCENT; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUDIOMETRY; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; CISPLATIN; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HAIR CELLS, OUTER; HEARING LOSS, SENSORINEURAL; HUMANS; INFANT; MALE; NEOPLASMS; OXIDATIVE STRESS; RETROSPECTIVE STUDIES;

EID: 5344235479     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mph.0000141348.62532.73     Document Type: Article

References (49)

1. Doz F, Pinkerton R, Pacquement H, et al. Platinum derivatives in pediatric oncology. Arch Fr Pediatr. 1993;50:353-359.
2. Gaynon PS. Carboplatin in pediatric malignancies. Semin Oncol. 1994;21(5, Suppl 12):65-76.
3. Hartmann O, Pinkerton CR, Philip T, et al. Very-high-dose cisplatin and etoposide in children with untreated advanced neuroblastoma. J Clin Oncol. 1988;6:44-50.
4. Pinkerton CR, Zucker JM, Hartmann O, et al. Short duration, high dose, alternating chemotherapy in metastatic neuroblastoma. (ENSG 3C induction regimen). The European Neuroblastoma Study Group. Br J Cancer. 1990;62:319-323.
5. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf. 1995;13:228-234.
6. Erdlenbruch B, Nier M, Kern W, et al. Pharmacokinetics of cisplatin and relation to nephrotoxicity in pediatric patients. Eur J Clin Pharmacol. 2001;57:393-402.
7. Doz F. Carboplatin in pediatrics. Bull Cancer. 2000;87:25-29.
8. Murry DJ. Comparative clinical pharmacology of cisplatin and carboplatin. Pharmacotherapy. 1997;17:140S-145S.
9. Frappaz D, Michon JM, Hartmann O, et al. Etoposide and carboplatin in neuroblastoma: a French Society of Paediatric Oncology phase II study. J Clin Oncol. 1992;10:1592-1601.
10. Los G. Platinum dose-intensity. J Infus Chemother. 1996;6:64-68.
11. Shaw PJ, Pinkerton CR, Yaniv I. Melphalan combined with a carboplatin dose based on glomerular filtration rate followed by autologous stem cell rescue for children with solid tumors. Bone Marrow Transplant. 1996;18: 1043-1047.
12. Matthay KK, O'Leary MC, Ramsay NK, et al. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results. Eur J Cancer. 1995;31A:572-575.
13. English MW, Skinner R, Pearson AD, et al. Dose-related nephrotoxicity of carboplatin in children. Br J Cancer. 1999;81:336-341.
14. Freilich RJ, Kraus DH, Budnick AS, et al. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue. Med Pediatr Oncol. 1996;26:95-100.
15. Parsons SK, Neault M, Lehmann LE, et al. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant. 1998;22:669-674.
16. Brock P, Bellman S. Ototoxicity of cisplatinum. Br J Cancer. 1991;63: 159-160.
17. Ding DL, Wang J, Salvi R, et al. Selective loss of inner hair cells and type-I ganglion neurons in carboplatin-treated chinchillas. Mechanisms of damage and protection. Ann NY Acad Sci. 1999;884:152-170.
18. Hinojosa R, Riggs LC, Strauss M, et al. Temporal bone histopathology of cisplatin ototoxicity. Am J Otol. 1995;16:731-740.
19. Evans P, Halliwell B. Free radicals and hearing. Cause, consequence, and criteria. Ann NY Acad Sci. 1999;884:19-40.
20. Dehne N, Lantermann J, Petrat F, et al. Cisplatin ototoxicity: involvement of iron and enhanced formation of superoxide anions radicals. Toxicol Appl Pharmacol. 2001;174:27-34.
21. Newell DR, Pearson AD, Balmanno K, et al. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group. J Clin Oncol. 1993;11:2314-2323.
22. Brock PR, Bellman SC, Yeomans EC, et al. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol. 1991;19:295-300.
23. Skinner R, Pearson AD, Amineddine HA, et al. Ototoxicity of cisplatinum in children and adolescents. Br J Cancer. 1990;61:927-931.
24. Dupont WD. Sensitivity of Fisher's exact test to minor perturbations in 2 x 2 contingency tables. Stat Med. 1986;5:629-635.
25. Hill JM, Speer RJ, Loeb E, et al. Clinical experience with cis-platinous diaminedichloride. In: Semonsky, Hejzlar, Masak, eds. Advances in Antimicrobial and Antineoplastic Chemotherapy, vol. 2. Baltimore: University Park Press, 1972.
26. McHaney VA, Thibadoux MA, Hayes FA, et al. Hearing loss in children receiving cisplatin chemotherapy. Pediatrics. 1983;102:314-317.
27. Schell MJ, McHaney VA, Green AA, et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol. 1989;7:754-760.
28. Ilveskoski I, Saarinen UM, Wiklund T, et al. Ototoxicity in children with malignant brain tumors treated with the "8 in 1" chemotherapy protocol. Med Pediatr Oncol. 1996;27:26-31.
29. Walker DA, Pillow J, Waters K.D, et al. Enhanced cis-platinum ototoxicity in children with brain tumours who have received simultaneous or prior cranial irradiation. Med Pediatr Oncol. 1989;17:48-52.
30. Pasic TR, Dobie RA. Cis-platinum ototoxicity in children. Laryngoscope. 1991;101:985-991.
31. Berg AL, Spitzer JB, Garvin JH. Otologic impact of cisplatin in paediatric oncology patients. Laryngoscope. 1999;109:1806-1814.
32. Fjermedal O. Hearing identification in difficult to test children. A study of 142 infants and children. Scand Audiol. 1989;18:185-191.
33. Park KR. The utility of acoustic reflex thresholds and other conventional audiologic tests for monitoring cisplatin Ototoxicity in the pediatric population. Ear Hear. 1996;17:107-115.
34. Bokemeyer C, Berger C, Hartmann JT, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer. 1988;77:1355-1362.
35. Dini G, Lanino E, Rogers D, et al. Resistant and relapsing neuroblastoma: improved response rate with a new multiagent regimen (OC-HDP) including high-dose cisplatinum. Med Pediatr Oncol. 1987;15:18-23.
36. Brock P, Pritchard J, Bellman S, et al. Ototoxicity of high-dose cisplatinum in children. Med Pediatr Oncol. 1988;16:368-369.
37. Stern JW, Bunin N. Prospective study of carboplatin-based chemotherapy for paediatric germ cell tumors. Med Pediatr Oncol. 2002;39:163-167.
38. Macdonald MR, Harrison RV, Wake M, et al. Ototoxicity of carboplatin: comparing animal and clinical models at the Hospital for Sick Children. J Otolaryngol. 1944;23:151-159.
39. Waterhouse DM, Reynolds RK, Natale RB. Combined cisplatin and carboplatin. Cancer. 1993;15:4060-4066.
40. Humes HD. Insights into ototoxicity. Analogies to nephrotoxicity. Ann NY Acad Sci. 1999;884:15.
41. Dominici C, Petrucci F, Caroli S, et al. A pharmacokinetic study of high dose continuous infusion cisplatin in children with solid tumors. J Clin Oncol. 1989;7:100-107.
42. Murakami T, Inoue S, Sasaki K, et al. Studies on age-dependent plasma platinum pharmacokinetics and ototoxicity of cisplatin. Semin Cancer Therapy. 1990;6:145-151.
43. Peng B, English MW, Boddy AV, et al. Cisplatin pharmacokinetics in children with cancer. Eur J Cancer. 1997;33:1823-1828.
44. Peng B, Boddy AV, English MW, et al. The comparative pharmacokinetics and pharmacodynamics of cisplatin and carboplatin in paediatric patients: a review. Anticancer Res. 1994;14:2279-2283.
45. Peters U, Preisler-Adams S, Hebeisen A, et al. Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000;11:639-643.
46. Moore JK. Maturation of human auditory cortex: implications for speech perceptions. Ann Otol Rhinol Laryngol Suppl. 2002;189:7-10.
47. Tibussek D, Meister H, Walger M, et al. Hearing loss in early infancy affects maturation of the auditory pathway. Dev Med Child Neurol. 2002; 44:123-129.
48. Stavroulaki P, Apostolopoulos N, Segas J, et al. Evoked otoacoustic emissions-an approach for monitoring cisplatin induced ototoxicity in children. Int J Pediatr Otorhinolaryngol. 2001;59:47-57.
49. Barr RD, Chalmers D, De Pauw S, et al. Health-related quality of life in survivors of Wilms' tumor and advanced neuroblastoma: a cross-sectional study. J Clin Oncol. 2000;18:3280.